{"altmetric_id":1086330,"counts":{"readers":{"mendeley":0,"citeulike":0,"connotea":0},"total":{"posts_count":1},"twitter":{"unique_users_count":1,"unique_users":["JCPjrnl_online"],"posts_count":1}},"citation":{"abstract":"To compare the efficacy and safety of desvenlafaxine (administered as desvenlafaxine succinate) with placebo in reducing relapse rate in patients with major depressive disorder (MDD).","abstract_source":"pubmed","altmetric_jid":"4f6fa6223cf058f610007bef","doi":"10.1097\/jcp.0b013e3181c94c4d","first_seen_on":"2012-11-23T19:05:07+00:00","issns":["0271-0749"],"issue":"1","journal":"Journal of Clinical Psychopharmacology","last_mentioned_on":1353697503,"links":["http:\/\/journals.lww.com\/psychopharmacology\/Abstract\/2010\/02000\/Desvenlafaxine_for_the_Prevention_of_Relapse_in.4.aspx"],"pdf_url":"http:\/\/pdfs.journals.lww.com\/psychopharmacology\/2010\/02000\/Desvenlafaxine_for_the_Prevention_of_Relapse_in.4.pdf","pmid":"20075643","pubdate":"2010-02-01T00:00:00+00:00","publisher":"Elsevier Ltd","publisher_subjects":[{"name":"Medical And Health Sciences","scheme":"era"},{"name":"Psychology And Cognitive Sciences","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"startpage":"18","subjects":["psychopharmacology"],"title":"Desvenlafaxine for the Prevention of Relapse in Major Depressive Disorder: Results of a Randomized Trial","type":"article","volume":"30","mendeley_url":"http:\/\/www.mendeley.com\/research\/desvenlafaxine-prevention-relapse-major-depressive-disorder"},"altmetric_score":{"score":0.5,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":0.5},"context_for_score":{"all":{"total_number_of_other_articles":4504945,"mean":5.0973687710101,"rank":3175484,"this_scored_higher_than_pct":22,"this_scored_higher_than":1030070,"rank_type":"exact","sample_size":4504945,"percentile":22},"similar_age_3m":{"total_number_of_other_articles":279543,"mean":5.8363142068099,"rank":203151,"this_scored_higher_than_pct":20,"this_scored_higher_than":57060,"rank_type":"exact","sample_size":279543,"percentile":20},"this_journal":{"total_number_of_other_articles":1469,"mean":2.2032288828338,"rank":1105,"this_scored_higher_than_pct":18,"this_scored_higher_than":266,"rank_type":"exact","sample_size":1469,"percentile":18},"similar_age_this_journal_3m":{"total_number_of_other_articles":39,"mean":1.8644736842105,"rank":35,"this_scored_higher_than_pct":5,"this_scored_higher_than":2,"rank_type":"exact","sample_size":39,"percentile":5}}},"demographics":{"poster_types":{"science_communicator":1},"users":{"twitter":{"cohorts":{"Science communicators (journalists, bloggers, editors)":1}},"mendeley":{"by_status":[],"by_discipline":[]}}},"posts":{"twitter":[{"url":"http:\/\/twitter.com\/JCPjrnl_online\/statuses\/272053162112864256","license":"datasift","citation_ids":[1086330],"posted_on":"2012-11-23T19:05:03+00:00","author":{"name":"Jrnl Clin Psychophar","url":"http:\/\/www.psychopharmacology.com","image":"https:\/\/pbs.twimg.com\/profile_images\/1215775119\/psycho_normal.jpg","description":"Journal of Clinical Psychopharmacology keeps clinician-scientists & trainees up-to-date on the latest clinical developments in psychopharmacologic agents.","id_on_source":"JCPjrnl_online","tweeter_id":"238296432","geo":{"lt":null,"ln":null},"followers":80},"tweet_id":"272053162112864256"}]}}